Hydatiform mole: Difference between revisions

Jump to navigation Jump to search
Charmaine Patel (talk | contribs)
Charmaine Patel (talk | contribs)
Line 2: Line 2:
{{Hydatiform mole}}
{{Hydatiform mole}}


==Etiology==
The etiology of this condition is not completely understood. Potential risk factors may include defects in the egg, abnormalities within the [[uterus]], or nutritional deficiencies. Women under 20 or over 40 years of age have a higher risk. Other risk factors include diets low in [[protein]], [[folic acid]], and [[carotene]].


==Treatment==
==Treatment==

Revision as of 16:50, 19 September 2012

Hydatiform mole Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hydatiform mole from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hydatiform mole On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hydatiform mole

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hydatiform mole

CDC on Hydatiform mole

Hydatiform mole in the news

Blogs on Hydatiform mole

Directions to Hospitals Treating Hydatiform mole

Risk calculators and risk factors for Hydatiform mole


Treatment

Hydatidiform moles should be treated by evacuating the uterus by uterine suction or by surgical curettage as soon as possible after diagnosis. Patients are followed up until their serum human chorionic gonadotrophin (hCG) titre has fallen to an undetectable level. Invasive or metastatic moles often respond well to methotrexate. The response to treatment is nearly 100%. Patients are advised not to conceive for one year after a molar pregnancy. The chances of having another molar pregnancy are approximately 1%.

Prognosis

More than 80% of hydatidiform moles are benign. The outcome after treatment is usually excellent. Close follow-up is essential. Highly effective means of contraception are recommended to avoid pregnancy for at least 6 to 12 months.

In 10 to 15% of cases, hydatidiform moles may develop into invasive moles. These may intrude so far into the uterine wall that hemorrhage or other complications develop. It is for this reason that a post-operative full abdominal and chest x-ray will often be requested.

In 2 to 3% of cases, hydatidiform moles may develop into choriocarcinoma, which is a malignant, rapidly-growing, and metastatic (spreading) form of cancer. Despite these factors which normally indicate a poor prognosis, the rate of cure after treatment with chemotherapy is high.

Over 90% of women with malignant, non-spreading cancer are able to survive and retain their ability to have children. In those with metastatic (spreading) cancer, remission remains at 75 to 85%, although the ability to have children is usually lost.

References


External links

Acknowledgements

The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.

List of contributors:

Suggested Reading and Key General References

Suggested Links and Web Resources

For Patients

ar:حمل عنقودي nl:Mola-zwangerschap sv:Druvbörd

Template:WikiDoc Sources